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Director’s Report
Many exciting events have occurred
over the past year within our
oncology program. The most visible,
and perhaps the most tar-reaching,
was the recognition by the American

capabilities in both the Metro and
South Regions and have provided a
more complete array of
complementary therapies by
enhancing our art and music therapy

College of Surgeons’ Commission on
Cancer that the Metro Region Cancer
Program is truly an integrated cancer

programs. We are expanding our
genetic counseling service to areas
outside the Metro Region and are
utilizing our research capabilities to

care provider. Having received ACoS
approval as a Network Cancer
Program, Aurora Health Care’s
Metro Region is one of only eight in
the country to achieve this distinction.
This approval is granted only to
system facilities, which voluntarily
commit to provide the best in
diagnosis and treatment of cancer and
also choose to undergo a rigorous
evaluation process and performance
review. We are most proud that the
dedicated efforts of our physicians
and staff allowed us to join this elite
group of Network Cancer Programs.
During the past year, we increased
the number of our Vince Lombardi
Cancer Clinics to twelve. We’ve
expanded our radiation therapy
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continue to grow our immunotherapy
and cell therapy programs.
The coming year’s challenge will be
to further integrate our operational
focus and committee structure into an
organization which maximizes our
ability to detect, prevent and treat
cancer while still allowing for a
community-based, local approach to
cancer care. Whether regionally or
locally, we are confident that a
combination of education, screening,
prevention, detection and treatment
is the correct approach for a
comprehensive oncology program.

William Laffey
Director, Cancer Services,
Aurora Health Care

Chairman’s Report
As Co-chairs of the Network Cancer
Committee, we are pleased to

our current videoconference efforts.
This has been especially helpful at

describe our progress in consolidating

Auora Medical Center in Hartford. The

three hospital cancer committees into
a single, regional body. We have

Quality Improvement Subcommittee
developed successful systems for

organized as a Regional Committee

tracking and reporting on the areas of
clinical trial participation, quality

with five subcommittees: Community
Outreach, Cancer Conference,
Dr. Jeffery A. Derus
Network Cancer
Committee Chairman,
Clinic of Urology, SC

Registry Data, Quality Improvement
and Clinical Management. The latter
subcommittee is not required by the
American College of Surgeons, as are
the other tour, but it was determined

outcome studies and patient care
improvements. This was a massive
task across the region but the results
have been worth the effort. We have a
tremendous baseline platform from

that the complexity of our organiza

which to grow. A similar process was
completed by the Community

tion warranted such an addition.

Outreach Subcommittee regarding

Much of our first year was spent on
organizational issues: we reviewed

regional consolidation of outreach
activities, speaking engagements and

committee functions, refined

health fairs. Quality issues were by no
means neglected as the Clinical

membership, and focused committee

Management Subcommittee

meetings on subcommittee reports

commissioned a study at St. Luke’s
Medical Center to improve the

and educational offerings to our
members. We held numerous sessions
at the hospital sites to determine how
best to transition from three

process of chemotherapy delivery to
in patients in order to decrease errors
and increase timeliness.

committees into one.
Most of our committee goals for the

It has been an active year and one for
which we take pride. As one of few

year were directed toward

approved networks in the country,

determining baselines and standards

we found that we had very few road

for capturing the information

maps to follow from other

currently compiled throughout the

organizations. We have covered new

region. Our Cancer Conference
Subcommittee determined demand

ground in very creative ways, all with
the goal of quality patient care for

for increasing our videoconferencing

those who entrust their care to our

capabilities, and we then expanded

health care providers.
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Cancer Conference Report
Multidisciplinary Cancer Conferences
take place weekly in the Metro Region
of Aurora Health Care.
Tumor Board Conferences meet
regularly at noon each Friday and
provide an opportunity for current
case discussion and continuing
education. The conferences facilitate
the exchange of ideas between the
departments of Medical Oncology,
Pathology, Radiology, Radiation
Oncology and Surgery, as well as all
other ancillary services involved in the
care and treatment of cancer patients.
Case presentations cover all major

radiological and surgical findings,
pre-treatment evaluation, treatment
modalities and follow-up care. Patient
names are always withheld to protect
confidentiality and privacy.
Representatives from all disciplines are
encouraged to present cases at the
conferences and to express their
opinions concerning diagnosis and
treatment. Participation in
multidisciplinary case review and
management discussions aids in the
exchange of new information and
knowledge. This helps in achieving

cancer sites seen within the Network
and include pertinent case details,

the goal of providing consultative
services to patients, educating the
medical staff, and improving care for

presentation of pathological,

all cancer patients.
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Cancer Registry Report
The Cancer Registry of the Metro
Region is managed and staffed by

patient outcome, facilitating research,
assisting with marketing, administra

Certified Tumor Registrars and is in
compliance with state statutes and
American College of Surgeon (ACoS)
requirements. The registrars

tive planning and quality benchmark
purposes. All information is kept
strictly confidential and only

coordinate and attend cancer
conferences, participate in cancer
Lisa Robinson
Regional Manager,
Clinical Data Registries

aggregate data is released. Both
inpatients and outpatients are

committee meetings and complete
physician-assisted quality control

included in the registry database. In
addition, at the request of the Cancer
Committee, certain benign and

studies on 70% of the yearly analytic
caseload.

borderline tumors are also included.
Data is submitted yearly to the

The registrars enter data into a
combined multi-hospital Internetbased software program that serves
the Metro and South Region hospitals.
All facilities are able to enter data,
which can then be combined and
pulled up from any location as
needed for purposes of assessing

National Cancer data base (NCDB)
and is reviewed for completeness,
accuracy and timeliness.
We hope you enjoy this year’s annual
report that takes an in-depth look into
the treatment and outcome of those
with rectal cancer.
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Colorectal Cancer Screening
This year approximately 58,000

expertise (Table 1). Incorporating

Americans will die from colorectal

these factors in the decision-making

cancer. It is the second leading cause

process may increase the likelihood of

of cancer death in both men and

screening. In addition, increasing

women, and accounts for 10% of

public awareness may lead to better

cancer deaths overall.

adherence to evidence-based
screening guidelines.

Despite current evidence that
colorectal cancer screening can

People at increased risk for colorectal

decrease mortality from colorectal

cancer should be approached

cancer by 50%, screening rates in the

differently. For example, those with a

population remain very low. Because

first-degree relative (parent, sibling or

screening tests make it possible to

child) with colon cancer or

detect early tumors at a treatable

adenomatous polyps diagnosed at

stage, we need to focus our attention

age <60 years or two first-degree

on persons without symptoms of

relatives diagnosed with colorectal

colorectal cancer if we are to make an

cancer at any age should be advised

impact in survival. According to a

to have screening colonoscopy

1998 National Health Survey, only 20

starting at age 40 years or 10 years

to 30 percent of eligible respondents

younger than the earliest diagnosis in

reported having had tecal occult

their family, whichever comes first,

blood testing during the preceding

and repeated every five years.

two years, and only 5 to 21 percent
had a screening endoscopy during the

In recent years, we have seen dramatic

preceding three years.

advances in the technical aspects of
colon cancer screening. However, we

Experts agree that men and women

still have quite a ways to go in terms

over the age of 50, i.e., people at

of making our tests more convenient

average risk, need to undergo

(e.g., more tolerable bowel

colorectal cancer screening with any

preparation) and acceptable (e.g.,

one (or a combination) of the

more respectful of our patient’s

modalities listed in Table 1. Because

privacy). Future advances will likely

there is no single test of unequivocal

include more accurate noninvasive

superiority, the decision on which

screening tests, and the development

screening tool to choose depends on

of familial genetic testing that can be

patient and physician preference, as

used in the general population.

well as available equipment and
6

Dr. Lyndon Hernandez
GI Consultants, Ltd

Table 1. Colorectal Cancer Screening Modalities
Test

Pros

Cons

Fecal occult
blood test

• Convenient
• Inexpensive

Significant false positive
and false negative rate

Sigmoidoscopy

• Can be performed
without sedation
• Shown to reduce
mortality (casecontrol studies)

Can miss proximal
colon lesions

Barium enema

No sedation required

If positive, often leads to
colonoscopy

Colonoscopy

Permits removal of
polyps throughout
the colon

Invasive

Virtual colonoscopy

• Non-Invasive
• Technology
improving but clinical
utility still being
determined

•

•

Not sensitive for
small polyps
Not covered by
most insurers

Gender of Patients with Rectal Cancer

• According to the
National Cancer
data base (NCDB),
males account for
57% of the incidence
of colorectal cancer,
whereas females
account for 43%.
• In AHC-Metro Region
58% were male and
42% were female.

70%
60%
50%
40%
30%
20%

70%
0%

Male

•Metro

Female

103 NCDB
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Radiology and Diagnostic Imaging
of Rectal Cancer
In patients with rectal cancer,
prognosis and treatments are
dependent on accurate staging of

inaccurate in determining
involvement of regional lymph nodes
(60% to 80% accuracy). CT, US and

disease. Evaluation of rectal cancer
should address the depth of tumor
invasion into or through the wall of

MRI evaluation of lymphadenopathy
relies on change in size of nodes,
which is not sensitive for detection of

the rectum, local disease in the pelvis,
including lymph node involvement,
and distant metastatic disease.

metastatic involvement. Unfortunately,
lymph nodes can become positive
with malignancy before they become

Imaging is important for pretreatment
assessment, as well as follow-up

enlarged. Other imaging modalities
must be used to assess tumor margin
and regional lymph nodes (multide

studies. The imaging modalities
available for rectal cancer include
computerized tomography (CT scan),

tector CT, US and MRI).

endorectal ultrasound (EUS),
magnetic resonance imaging (MRI),
and positron emission tomography

Recently, improved CT imaging with
multidetector CT scanners has shown
an improvement in accuracy of

(PET). Initial workup should also
include evaluation of the entire colon
for concomitant colorectal tumors,

staging. The use of multidetector
scanners with rectal distention by an
air balloon device, and both sagittal
and coronal reconstruction images,
improve tumor detection (90% to

either with colonoscopy or
barium enema.
CT imaging is a high-resolution
imaging modality with very reliable
technique, and is the mainstay of
rectal cancer imaging. It is an
excellent means of evaluating for
distant metastases, including lung
and liver metastatic disease, at the
same time assessing for regional
disease in the pelvis. Unfortunately,
conventional CT scan is relatively
inaccurate in assessing mural depth of
tumor in the rectum (only up to 79%
accurate), and also is relatively
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700% accurate) and detection of
depth of tumor invasion over
conventional CT.
Endorectal ultrasound (EUS) can
accurately (80% to 95%) stage mural
depth of tumor, and can also offer
EUS-guided fine needle biopsy of
masses or even abnormal sized lymph
nodes. Please see in-depth
article on this modality.
US is user-dependent in its accuracy
and is not available in all areas.

Dr. Daniel Rapp
Great Lakes Radiologists, SC

MRI with either external detector
coil or endorectal coil is a useful

positive uptake. Unfortunately,
false positive uptake is also

reliable, reproducible examina
tions which can detect initial

means of detecting local
invasion of tumor, but faces

possible. PET lacks spatial
resolution, but images can be
fused with CT scan images to
yield a higher specificity of
positive uptake. PET scanning is

stage of disease, as well as serial
reassessment for follow up.

similar limitations of nodal
detection as other modalities.
PET scan imaging utilizes
chemical and metabolic changes
in tumor tissues. Tumor tissue or

not readily available in all areas.
To summarize, diagnostic
imaging of rectal cancer requires

lymph nodes are shown as

Many imaging modalities are
available, each with individual
strength and limitations. By
combining multiple studies in an
individualized fashion, accurate
assessment of rectal cancer can
be achieved.

Rectal Cancer Stage at Diagnosis
Data from the NCDB
Annual Review of Rectal
Cancer indicates that
Stage I disease is
diagnosed most frequently
(27%). As illustrated in the
accompanying graph,
7% more Stage I cases
were diagnosed within
AHC Metro Region 34%
compared to (27%). More
Stage II, Stage Ill and
Stage IV cancers were
also diagnosed, whereas
the NCDB had 9% more
unknown cases.

35%

30%
25%
20%
15%
10%
5%

0%
Stage 0

Stage 1

Stage 2

Metro

Stage 3

Stage 4

Unknown

•03 NCDB
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Endoscopic Ultrasound in Staging Rectal
Cancers: Gimmick or Godsend?
Rectal endoscopic ultrasound (EUS),
which is an endoscope equipped with

Why EUS?

a high-frequency ultrasound probe,
has emerged as an accurate imaging

often curable by surgery when
localized. The prognosis of rectal

test for staging rectal cancer. By
providing high-resolution images of

cancer is primarily related to the
degree of tumor depth and the

tumor depth and lymph node
involvement, the information
gathered from EUS can assist the

presence or absence of nodal
involvement. Accurate staging using

clinician in directing therapy for
patients with rectal cancer.
Accuracy
Preoperative staging procedures for
rectal cancer include computed
tomographic (CT) scan, magnetic
resonance imaging (MRI) scan, and

Rectal cancer is highly treatable and

EUS can influence therapy by helping
to determine which patients may be
candidates for preoperative
chemotherapy and radiation therapy
to maximize the likelihood of
resection with clear margins, and
which patients may be candidates for
local excision or sphincter-preserving
operation rather than a permanent

EUS. The TNM classification is
commonly used to stage rectal

colostomy.

cancer. T stage involves depth of
tumor invasion into the rectal wall,

All of this sounds great, but in the real
world it may not always be as simple.

while N and M stages refer to the
presence or absence of lymph node

Managing rectal cancer is often
challenging, and this is why

and distant metastasis, respectively.
For T and N staging, EUS is superior to

neoadjuvant therapy is increasingly
used in the context of EUS to improve

CT and MRI (Table 1). Although widely
accepted as the procedure of choice
for loco-regional staging, EUS is by no

the chance of cure and enhance the
quality of life of these patients.

means a replacement for other imag
ing tests such as CT scan. Because CT

High rate of local recurrence

after surgery

can detect distant metastasis whereas
EUS cannot, these 2 modalities are in

The presence of the bony pelvis
makes it difficult to obtain wide

fact complementary to each other.

surgical margins. In those patients
with advanced disease, the local
recurrence rate following surgery is
up to 50% (higher compared to colon

Jo

Dr. Lyndon Hernandez
Cl Consultants, Ltd

cancer) and often ultimately
results in death. Thus, adjuvant

patients who would have been
denied of this treatment had

preoperative staging procedure

or neoadjuvant therapy is
utilized to address this issue.

they undergone CT alone. This is
because CT can inaccurately

of choice for rectal cancer
because its ability to evaluate

Interestingly, preoperative

understage rectal cancer in up

taging using both CT and EUS
resu Its in more frequent use of

to one-third of patients. It is

tumor depth and lymph node
involvement is superior to CT

important to understand the

scan or MRI. More importantly,

neoadjuvant therapy than if
staging was performed with

phenomenon of upstaging by
EUS, because neoadjuvant

adding EUS to the standard

CT alone. It appears that by

therapy can diminish local

upstaging tumors, the

recurrence rates of transmu rally

information gathered from EUS
can change management by

infiltrating (T3 or T4) rectal

In conclusion, EUS is the

work-up of these patients leads
to a change in management
(neoadjuvant therapy) in
one-third of patients.

tumors.

directing neoadjuvant therapy to
Table 1. Accuracy of EUS, CT scan and MRI in rectal cancer staging
T Stage (%)

N Stage (%)

EUS

80

CTScan

65—75

55—65

MRI

75—85

60—65

—

95

70

—

75

Histologies of Rectal Cancer
Histology

AHC Metro Region

NCDB

Adenocarcinoma

66%

67.20%

Adenocarcinoma
in adenomatous polyp

2%

4.6%

Adenocarcinoma
in villous adenoma

2%

3.1%

Adenocarcinoma in
tubulovillous adenoma

16%

7%

Mucinous
adenocarcinoma

2%

3.1%

Other

12%

15%

Total

100%

100%
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Pathology
Colorectal carcinoma is the fourth
most common cancer in the United

the muscularis mucosa is present.
Once this occurs, the patient has an

States, with approximately 150,000
new cases diagnosed each year.

invasive adenocarcinoma which must

Colorectal carcinoma accounts for
approximately 58,000 deaths per
year, comprising nearly 15% of all
cancer related deaths in the United
States. Peak incidence for colorectal
carcinoma is age 60 to 70. Less than
20% of cases occur in patients under
50 years of age. Rectal carcinomas

be resected.
Pathologists evaluate many items
after receiving a rectal resection
specimen. The tissue is “grossed”
and tissue sections are placed in
cassettes for histologic processing.
The end result of this process is the

i

Dr. David A. Scalzo
Laboratory Medical Director,
Aurora Medical Center in Kenosha

formation of hematoxylin and eosin
stained glass slides which are

or beyond the muscularis propria
into the subserosa, adjacent adipose

carcinoma group.

evaluated under a microscope. The
following factors are assessed when

tissue or adjacent organs. Simply
put, the deeper the tumor invades,

The rectum normally measures
approximately 12 cm in length. The

evaluating rectal adenocarcinomas:
• Histologic grade
• Extent of invasion
• Blood/lymphatic vessel invasion
• Extramural venous invasion

the worse the prognosis. Additional
adverse prognostic factors include

are a subset of the colorectal

rectum is covered by peritoneum in
front and on both sides in its upper
third and only the anterior wall in its
middle third. There is no peritoneal
covering in the lower third.

• Perineural invasion
• Peritumoral lymphocytic response
• Specimen margins

blood/lymphatic vessel invasion,
extramural venous invasion and
perineural invasion. Metastatic
adenocarcinoma in regional lymph
nodes is an additional adverse
prognostic factor. The tumor is

• Regional lymph nodes

classified as Ni if metastasis is seen in
1 to 3 regional lymph nodes. The

The histologic grade is defined
as follows:
• Well differentiated =
95% gland forming
• Moderately differentiated =
50%—94%glandforming

tumor is categorized as N2 if there is
metastasis in 4 or more regional

configuration or a combination of the
two (“tubulovillous adenomas”).

• Poorly differentiated

margins are evaluated.

Adenomas with high grade dysplasia
demonstrate increasing cytologic and

• Undifferentiated =
<5% gland forming

The majority of rectal carcinomas are
adenocarcinomas. Many patients
have dysplastic or “pre-malignant”
rectal polyps, which may evolve into
adenocarcinoma if left untreated.
Dys plastic or adenomatous polyps
may have a tubular architectural
configuration, a villous architectural

architectural atypia. A lesion becomes
an invasive adenocarcinoma if
glandular invasion into or through
12

5%

—

=

lymph nodes. Margins are also
assessed to ensure that the tumor has
been completely resected. Proximal,
distal, serosal and radial/mesenteric

49% gland forming

Extent of invasion is classified as into
the submucosa, muscularis propria

The information provided by the
pathologist concerning the rectal
carcinoma patient is incorporated
into the tormulation of a treatment
plan for the patient.

Surgical Treatment of Rectal Cancer
Approximately 40,000 new cases of
rectal cancer are diagnosed each
year. Although many of these tumors
require radical resection, with earlier
detection more local procedures are
now possible. Advantages of local
therapy are preservation of the anal
Dr. Markian j. Kuzycz
Department of General
Surgery, Aurora Medical
Cente, in Kenosha

margins and resectability of lower
rectal tumors. In addition,
preoperative chemo and radiation
therapies have been shown to reduce
the degree of rectal wall invasion and
lymph node involvement in up to
70% of patients.3 Preoperative

sphincter, avoidance of a colostomy,
and avoidance of radical pelvic

treatment to “downstage” the tumor
is preferred as post operative tissues

surgery with improved quality of life.

are relatively ischemic and
chemotherapy is not as effective then.
With new techniques, smaller distal

Initial assessment of intent of surgery
(palliative versus curative) must be
made, and if curative resection is
possible, location and staging of the
tumor must be considered. Location
of the tumor, proximal two-thirds of
the rectum versus distal one-third, is
key. For resectable tumors in the
proximal to mid rectum, a low
anterior resection (LAR) is the
procedure of choice. Most cases do
not require a proximal colostomy as
circular stapling devices (EEA) allow
for a very low anastamosis with little
technical difficulty. Also, pathologic
studies have shown that distal spread
beyond two centimeters is extremely
rare and, in tumors that do, survival is
poor regardless of clear distal

resection margins and pre-op
chemo-radiation, most rectal tumors
may be resected with [AR.
Distal rectal tumors have traditionally
been treated with the Miles Procedure
or APR (abdomino-perineal resection).
This involves resection of the rectum,
anus and permanent perineal closure
with creation of a permanent
colostomy. However, patients with
limited disease, stages Ti -T2 (Table 1),
have been successfully treated with
sphincter-sparing procedures. Today,
staging of early rectal tumors is most
accurate with endoscopic ultra
sonography.

margins.2 This allows for smaller distal

continued on next page
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Table 1.
Primary Carcinoma (T)
In situ
Tis

Ti
T2
13
T4

Submucosal invasion
Muscularis propria invasion
Perirectal fat invasion
Invasion of adjacent organ

Regional Lymph Nodes (N)
No Nodes
NO
1-3 perirectal nodes
Ni
>3 regional nodes
N2
N3

Metastases

MO
Mi

No metastases
Metastases

Stage
1 11-2, NO,MO
2 13-4, NO, MO
311-4, N1-3,MO
4 1 any, N any, Mi

5-yr Survival
75%

—

85%

55%—77%

3O%—44%
<25%

Metastases to node along named
vascular trunk

Clin. 2002;52:23-47
‘Jemal A., Thomas A., Murray I., Thun M. Cancer Statistics, 2002. CA Cancer I
ity and ultimate survival. B)M
e
mortal
perativ
2McA rUle CS, Hole D. Impact of variability among surgeons on post-o
199 J;302:1501-1S0S
rectal cancer: Its impact on stage of disease
3Bernini A. et all. Preoperative adjuvant radiation with chemotherapy for
35
:731-1
and the role of endoscopic ultrasound. Ann Surg Oncol 1996:3

Cob-anal anastamosis is performed in younger
patients with favorable body habitus and involves
rectal resection with careful preservation of the
sphincter muscles to anastamose the signjoid colon

to the anal verge. Local/transanal excision is
possible if the tumor is small, mobile and superficial.
Fulguration uses electrocautery to destroy the tumor
through the entire rectal wall. The above mentioned
sphincter-sparing procedures, however, must be used
in a select group of patients who have been
accurately staged at an early stage preoperatively.
Understaging can be disastrous as later stage tumors,
>12, have much greater recurrence rates, and in rectal
cancer recurrence is usually incurable.
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Laparoscopic resections have also recently become
an option, however many authors question the
possibility of a surgical cure. Of course laparoscopy
has an advantage of decreased post-operative pain
and shorter hospital stays, however adequacy of
lymphadenectomy remains controversial.
In summary, rectal cancers, if resectable, are treated
based on their location. Tumors in the proximal
two-thirds require LAR. Distal tumors at a late stage
and those involving the sphincter muscles require
APR, while early stage tumors can be treated with a
variety of sphincter-sparing procedures.

• A multidisciplinary approach to
treating rectal cancer is evident in
the Metro Region of Aurora Health
Care, as 48% of cases were treated
with a combined modality approach.
• 34% were treated with surgery,
radiation and chemotherapy vs.
30% nationally.
• 14% were treated with surgery and
chemotherapy vs. 4% nationally.
• Surgical resection alone of the
primary tumor was done in the
majority of the cases reported
through the NCDB at 40%. Definitive
surgery alone in the Metro Region of
Aurora Health Care was 24%. The
difference can be accounted for, due
to the number of patients with
advanced stage at diagnosis.
• Graph Key:
S = Surgery
C = Chemotherapy
R = Radiation
N = No Treatment

Treatment Modalities for Rectal Cancer

Treatment Types
50%
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%

SRC

S

SC

SR
• Metro

RC

C

N

Other

• NCDB

Surgical Approach to Rectal Cancers
40
35
30
25
20

19

15
10
5
0
Local
Excision

Wedge or
Segmental

Pull
Through

• Metro

A/P
Resection

Proctolectomy

En Bloc
Resection

None

03 NCDB
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Chemotherapy for Rectal Cancer
Rectal cancer is a relatively common
disease in the United States.
Approximately 40,000 patients are
diagnosed with this malignancy every
year and 8,500 patients die from it. While
surgery remains the primary treatment
for rectal cancer, this malignancy is
rapidly becoming the model for
multidisciplinary management of solid
tumors. Chemotherapy is an important
part of neoadjuvant or pre-operative
treatment, as well as adjuvant therapy
aimed at eradicating micrometastatic
disease. It is the mainstay of palliative
treatment of patients with metastatic
rectal cancer.
Adjuvant Therapy
In contrast to colon cancer, where the
failure pattern is predominantly distant
metastases, an analysis of site of first
failure in patients with rectal cancer
indicates an equal distribution locally in
the pelvis and distally (liver and lung).
Local recurrence is mainly related to
difficulties in obtaining optimal surgical
clearance of the radial margin. Local
failure is a component of first failure in
less than 10% of patients with 11-2
disease. This goes up to 30% for 13N0

disease and can be as high as 65% in
stage 13-4, NJ-2 disease.
A meta-analysis has amply demonstrated
that radiation therapy can reduce the
rate of local recurrence without
necessarily prolonging survival.
However, chemotherapy, when added

16

to radiation, can positively influence
survival. Clinical trials have established
the following facts regarding adjuvant
therapy in rectal cancer:
• The risk of local recurrence with
chemotherapy plus radiation (CMI) in
Stage Il/Ill rectal cancer is 33% versus
55% with surgery alone (GIISG 7175)
• Compared to radiation (RI) alone,
CMI reduces the likelihood of distant
relapse by 37% and overall death rate
by 29% (NCCTG)
• 5FU, when given as continuous
infusion rather than in bolus fashion
during RI, improves the overall
survival from 60% to 70% (INI 864751)
• Addition of leucovorin and levamisole,
or giving 5FU as continuous infusion
rather than in bolus fashion before
and after RI, does not improve
survival (INI 01 44)
Iherefore, the standard of care is to
administer 5FU as bolus injection five
days in a row, every 28 days for two
cycles before radiotherapy, followed by
RT plus 5FU as continuous infusion,
followed by two more cycles of 5FU as
administered pre-radiotherapy.
Neoadjuvant Therapy
Neoadjuvant or pre-operative therapy is
utilized to promote tumor regression in
patients with distal rectal tumors. The
goal of preoperative treatment is to
convert the surgical procedure from an
APR to sphincter-sparing operation,
such as LAR with coloanal anastomosis.

Dr. Malik Bandealy
Oncology Alliance, SC

Because of the success of CMI in the
post-operative setting, there is
intense interest in using this
approach neoadjuvantly. Following
moderate to high dose RI (45 to 50
Gy), pathological complete response
(pCR) occurs in only 6% 12%,
while addition of 5FU based
chemotherapy to RI increases the
pCRto 16%—31%. Preliminary data
support a beneficial effect of tumor
downstaging on both local control
and survival. Roswell Park Cancer
Institute’s experience presented in
—

May 2003 at the American Society of
Clinical Oncology meeting indicates
improvement in overall survival in
patients who experienced tumor
downstaging (Median 45.3 months
for the whole group versus 73.2
months for the downstaged group).
Downstaging of I status occurred in
33% of patients.
Therefore, all patients with distal
rectal cancers, i.e., within 6 cm of the
anal verge, who have been
determined by endorectal ultrasound
to have at least a 13 lesion, are
candidates for neoadjuvant
chemo-radiotherapy. These patients
are treated with RI plus continuous
infusion of 5FU.

Metastatic Disease
In metastatic colorectal cancer,
chemotherapy has been shown to
improve quality of life and survival.
For many years, 5FU plus leucovorin
had been the standard of care. This
has a response rate of 15% with
median survival of 11 months.
Recently reported clinical trials have
established the following facts
regarding chemotherapy for
metastatic colorectal cancer:
• Intravenous 5FU plus leucovorin
and oral 5FU (Xeloda) are
equivalent in survival and
response rate
• Addition of CPI-J 1 (Cam ptosar) to
5FU plus leucovorin improves the
rate to 30% and survival to 15-16
months.
• Oxaliplatin plus 5FU plus
leucovorin is superior in response
rate (40% vs. 30%) and survival
(19 vs. 15 months) to CPI-1 1 plus
5FU plus leucovorin
Therefore, 5FU plus leucovorin plus
Oxaliplatin!CPI-1 1 should be the
new standard for chemotherapy in
this disease, at least for patients with
good performance status. Older
patients can be treated with oral
Xeloda.

Future Direction
The incorporation of newer agents
such as CPI-1 1 and Oxaliplatin in
adjuvant programs is likely to
improve the surgical cure rate seen in
Stage Il/Ill rectal cancer. Clinical trials
are underway, but it is logical to offer
a triple drug combination to younger
individuals with good performance
status off study.
A phase I/Il trial of neoadjuvant EU
plus CPI-1 1 with RI was recently
reported with encouraging results.
This needs to be explored further,
and is still investigational.
In metastatic disease, the addition of
Bevacizumab, an angiogenesis
inhibitor, to 5FU plus leucovorin plus
CPT-1 1 has been shown to improve
survival (20 months) in a recently
reported trial. There is also
considerable interest in C225,
another monoclonal antibody.
Therefore, the treatment of colorectal
cancer is entering the molecular age
of targeted therapy. This is likely to
improve cure rates and survival, and
decrease toxicity as treatments in
future are more likely to be target
specific.
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Radiation Therapy for Rectal Cancer
Rectal cancer affects approximately
40,000 people annually. It is estimated
that 8,500 people will die this year from
rectal cancer. Mortality from rectal
cancer has decreased over the past 30
years, possibly because of the earlier
diagnosis through screening and/or
better treatment modalities.
Surgery remains the primary treatment,
with radiation therapy and
chemotherapy functioning primarily
as adjuvant modalities. Low anterior
resection or coloanal anastomosis
preserve sphincter function. In cases
where an adequate resection would
be compromised by the location of
the tumor, it is necessary to do an
abdominoperineal resection.
In the adjuvant setting, randomized
studies have supported combined
chemotherapy and radiation therapy.
This treatment is indicated for
Stage T3-4 or NJ -2 disease. Local
control with adjuvant treatment is
60% 90%, with surgery alone at
50%% 75%. Survival at 5 years with
adjuvant treatment is 50% 70%,
with surgery alone 25% 50%.
Generally this involves six cycles of
postoperative chemotherapy plus
concurrent radiation during cycles 3
and 4. The radiation consists of 5-6
weeks of daily treatment utilizing
modern radiation therapy techniques.
—

—

—

—

The standard management for
low-lying rectal tumors is
abdominoperineal resection. There
has been increased interest in the use
of radiation therapy in an attempt to
preserve anal sphincter function.
Strategies include radiation therapy
alone, radiation therapy followed by
coloanal anastomosis or local
excision, local excision followed by
radiation therapy and preoperative
chemoradiation. These approaches
require careful selection of patients
for appropriateness.
Radiation alone: 5 year survival is
40% 50% for mobile lesions, 2%
4% for fixed lesions. Allow 2-4
months after completion of treatment
—

—

before making a decision regarding
salvage resection because these
tumors tend to regress slowly. It is
estimated that about 25% of
potentially resectable tumors
undergoing primary radiation therapy
achieve durable local control and are
able to avoid colostomy. However,
the control rates in patients with fixed
tumors is poor with radiation alone.
Local excision is appropriate in
patients with tumors confined to the
rectal wall in which there is a low
probability of lymph node metastases.
The selection criteria is:
Well or moderately well
differentiated histology
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Dr. Walter Wong
Radiation Oncology
Associates, Ltd.
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• Tumor size less than 4 cm
• Location 8 cm or less from the
anal verge

Preoperative vs. Postoperative
radiation: Swedish trial

• Mobile lesions
• Not ulcerated

randomized 474 patients, half to
preoperatively Z 25.5 Gy in one
week vs. 60 Gy split course postop

• No suspicion of perirectal or
pre-sacral nodes

control of the tumor and disease
free survival and overall. All
patients with pNo demonstrated
superior survival when compared to
pN+ patients. Finally, shrinkage of

eratively (13, NJ -2). Preoperative
radiation arm lead to improved

the tumor was directly associated
with superior survival.

Postoperative radiation is not
indicated for locally excised Ti
tumors unless the margins are
compromised or the histology

local control but no survival
advantage. Also the preoperative
arm resulted in decrease in small
bowel obstruction, and decreased
total grade 3+ non-hematologic

Preoperative vs. Postoperative
Chemoradiation: Currently the
NSABP R-03 in USA is randomizing

show poor differentiation or
angiolymphatic invasion.

toxicity (proctitis, cystitis, skin
fibrosis, and nerve symptoms).

neoadjuvant 5FU/Leucovorin/pelvic
XRT vs. 5FU/ Leucovorin! pelvic XRT.
The primary purpose of this study is

Preoperative chemoradiation can
be considered in patients who

to determine whether the administra
tion of preoperative chemotherapy
(SFU + Leucovorin) and radiotherapy,

Postoperative chemoradiation is
advised for T2 lesions. Patients with
T3 lesions are generally considered
for radical resection.
Preoperative radiation alone:
Eleven (11) modern radiation alone
trials for resectable lesions have
been reported. Only one trial
showed survival advantage. The
Swedish trial randomized 1,168
patients to either preoperative
radiation in which 25 Gy in one

refuse abdominoperineal resection
and who are not technically able to
undergo local excision because of
tumor size (13-4, NJ -2) or anatomic

followed by postoperative
chemotherapy is more effective than
the administration of postoperative
chemotherapy and radiotherapy in
improving the disease-free survival

constraints. Transrectal ultrasound
is commonly used to stage rectal
lesions preoperatively for muscle

and survival of patients with
operable carcinoma of the rectum.

invasion and nodal involvement.
The percentage of patients treated

The preliminary data (11 6 patients)
suggests that the preoperative

with preoperative radiation or
preoperative chemoradiation who

chemotherapy and radiation therapy
regimen used are at least as sage and
tolerablea standard postoperative

week (resected lesions) verses
surgery alone. The results showed
improvement in survival and local

are able to ultimately undergo low
anterior resection or coloanal

control versus surgery alone.
However, these results must be

anastomosis is quite variable at
30% 70%. Excellent sphincter

interpreted with caution given that
JO other randomized trials did not
show survival advantage.

functions is reported in 60% 70%
of patients. Recent trials indicate
downstaging of both the T stage
and the N stage was significantly

—

—

treatment. There was a trend to
tumor downstaging and sphincter
preservation in the preoperative arm.
Whether this arm will have greater or
lesser survival and long-term toxicity
awaits the completion of the study.

associated with improved local
—

19

Five-Year Survival Rates for Rectal Cancer Cases
In the Metro Region of Aurora Health Care, the five-year overall survival rate for those with rectal cancer is
slightly higher than that published by the National Cancer Database (NCDB), but not statistically significant.
See graph and table below.
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2002 and 2003 Metro Region Cancer Data
New Cases Breakdown

Analytical vs. Non-Analytical
(First Course vs. Subsequent Rx)
—

2002 and 2003 Analytical vs. Non-Analytical Breakdown of New Cancer Cases by Year of Diagnosis
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Benchmark Comparisons
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lop 5 Sites

When comparing the top five sites in order of decreasing frequency in the Metro Region to the
incidence of cancer cases reported by the state and the National Cancer Data Base (NCDB), it is
noted that the Metro Region sees a higher percentage of lung and leukemia cases, fewer prostate
cases than both the state and the nation, and a relatively equal number of breast and colorectal
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Race in 2002 and 2003
at St. Luke’s Medical
Hospital Review of new cases in 2002 and 2003 shows the population by race served
inantly white. By contrast,
predom
is
Hartford
in
Center
Medical
Center, West Allis Memorial Hospital and Aurora
with the majority being
tion
popula
diverse
more
a
serves
Center
the central city location of Aurora Sinai Medical
of African American descent.
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each facility, you can see that
In reviewing the percentages of males vs. females over a two-year time frame at
cant difference compared to
signifi
a
quite
is
and
facilities
four
many more females are being seen at three of the
however, may indicate a need for
the NCDB percentages. This is reflective of the fine women’s services provided;
ing.
men to be educated about the importance of regular check-ups and screen
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